Related Experiment Video
Updated: Sep 26, 2025

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation
Chengyue Wang1,2, Chengyuan Yu1,3, Haijiao Jing1
1Department of Hematology, The First Hospital of Harbin, Harbin Medical University, Harbin, China.
Insights
Long COVID, a thrombotic sequela, causes lasting health issues due to persistent inflammation and vascular damage. Early anticoagulation therapy shows promise in preventing complications and improving patient quality of life.
Area of Science:
- Medical Research
- Pathophysiology
- Thrombosis
Background:
- Long COVID sequelae reduce quality of life and increase healthcare burdens.
- Pathophysiological mechanisms include persistent viral replication, hypoxia, inflammation, and vascular endothelial damage.
- Thrombosis and vasculitis contribute to organ dysfunction and disease progression.
Purpose of the Study:
- To summarize evidence on coagulation abnormalities in long COVID.
- To focus on the pathophysiological mechanisms of thrombosis in long COVID.
- To review research on antithrombotic therapy for COVID-19 and long COVID.
Main Methods:
- Literature review of evidence for coagulation abnormalities in long COVID.
- Analysis of pathophysiological mechanisms, including the role of extracellular vesicles (EVs).
- Summary of recent research on antithrombotic therapy in COVID-19 and long COVID.
Main Results:
- Long COVID is characterized by persistent systemic vascular inflammation and dysfunction driven by thrombosis.
- Extracellular vesicles (EVs) contribute to thrombosis by carrying SARS-CoV-2 and expressing procoagulant factors.
- Pulmonary complications like hypertension, embolism, and fibrosis are common, exacerbating hypoxia and coagulation abnormalities.
Conclusions:
- Long COVID is fundamentally a thrombotic sequela with no current effective treatments.
- Early prophylactic anticoagulation may prevent thrombotic sequelae, protect vascular endothelium, and improve patient outcomes.
- Antithrombotic therapy offers a potential strategy to mitigate long COVID complications and enhance quality of life.
Abstract:
Many discharged COVID-19 patients affected by sequelae experience reduced quality of life leading to an increased burden on the healthcare system, their families and society at large. Possible pathophysiological mechanisms of long COVID include: persistent viral replication, chronic hypoxia and inflammation. Ongoing vascular endothelial damage promotes platelet adhesion and coagulation, resulting in the impairment of various organ functions. Meanwhile, thrombosis will further aggravate vasculitis contributing to further deterioration. Thus, long COVID is essentially a thrombotic sequela. Unfortunately, there is currently no effective treatment for long COVID. This article summarizes the evidence for coagulation abnormalities in long COVID, with a focus on the pathophysiological mechanisms of thrombosis. Extracellular vesicles (EVs) released by various types of cells can carry SARS-CoV-2 through the circulation and attack distant tissues and organs. Furthermore, EVs express tissue factor and phosphatidylserine (PS) which aggravate thrombosis. Given the persistence of the virus, chronic inflammation and endothelial damage are inevitable. Pulmonary structural changes such as hypertension, embolism and fibrosis are common in long COVID. The resulting impaired lung function and chronic hypoxia again aggravates vascular inflammation and coagulation abnormalities. In this article, we also summarize recent research on antithrombotic therapy in COVID-19. There is increasing evidence that early anticoagulation can be effective in improving outcomes. In fact, persistent systemic vascular inflammation and dysfunction caused by thrombosis are key factors driving various complications of long COVID. Early prophylactic anticoagulation can prevent the release of or remove procoagulant substances, thereby protecting the vascular endothelium from damage, reducing thrombotic sequelae, and improving quality of life for long-COVID patients.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis I: Introduction
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

